Trending Stock News

EPS for Chimera Investment (CIM) Expected At $0.61; Abeona Therapeutics (ABEO) Sellers Increased By 6.52% Their Shorts

Chimera Investment Corporation (NYSE:CIM) Logo

Abeona Therapeutics Inc (NASDAQ:ABEO) had an increase of 6.52% in short interest. ABEO’s SI was 8.71 million shares in April as released by FINRA. Its up 6.52% from 8.18M shares previously. With 986,900 avg volume, 9 days are for Abeona Therapeutics Inc (NASDAQ:ABEO)’s short sellers to cover ABEO’s short positions. The SI to Abeona Therapeutics Inc’s float is 31.26%. The stock decreased 1.52% or $0.3 during the last trading session, reaching $19.45. About 402,294 shares traded. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since April 16, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.

Analysts expect Chimera Investment Corporation (NYSE:CIM) to report $0.61 EPS on May, 7.They anticipate $0.10 EPS change or 19.61% from last quarter’s $0.51 EPS. CIM’s profit would be $114.57 million giving it 7.03 P/E if the $0.61 EPS is correct. After having $0.62 EPS previously, Chimera Investment Corporation’s analysts see -1.61% EPS growth. The stock increased 0.82% or $0.14 during the last trading session, reaching $17.15. About 420,651 shares traded. Chimera Investment Corporation (NYSE:CIM) has declined 12.70% since April 16, 2017 and is downtrending. It has underperformed by 24.25% the S&P500.

Chimera Investment Corporation operates as a real estate investment trust in the United States. The company has market cap of $3.22 billion. The company, through its subsidiaries, invests in residential mortgage-backed securities , residential mortgage loans, commercial mortgage loans, real estate-related securities, and various other asset classes. It has a 6.57 P/E ratio. The firm has elected to be taxed as a real estate investment trust.

Investors sentiment decreased to 0 in 2017 Q4. Its down 0.33, from 0.33 in 2017Q3. It dropped, as 0 investors sold Chimera Investment Corporation shares while 3 reduced holdings. 0 funds opened positions while 0 raised stakes. 928,173 shares or 3.99% less from 966,760 shares in 2017Q3 were reported. Nfc Ltd Limited Liability Company has 829,006 shares. Capital Invest Advsrs Ltd Llc holds 0.09% or 71,093 shares. Balasa Dinverno Foltz Limited Liability Corp stated it has 0.08% of its portfolio in Chimera Investment Corporation (NYSE:CIM).

Among 9 analysts covering Chimera Investment (NYSE:CIM), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Chimera Investment had 19 analyst reports since August 12, 2015 according to SRatingsIntel. As per Wednesday, March 23, the company rating was maintained by Nomura. The stock of Chimera Investment Corporation (NYSE:CIM) has “Hold” rating given on Thursday, February 15 by Keefe Bruyette & Woods. On Thursday, January 25 the stock rating was upgraded by Credit Suisse to “Outperform”. Barclays Capital maintained the stock with “Equal-Weight” rating in Tuesday, October 10 report. The firm has “Hold” rating by Deutsche Bank given on Tuesday, August 9. Wood maintained it with “Market Perform” rating and $15.50 target in Tuesday, August 9 report. The stock of Chimera Investment Corporation (NYSE:CIM) has “Buy” rating given on Wednesday, August 12 by Zacks. The firm has “Equal-Weight” rating given on Tuesday, October 13 by Barclays Capital. The rating was maintained by Deutsche Bank with “Hold” on Wednesday, August 12. Wells Fargo downgraded the shares of CIM in report on Monday, January 18 to “Market Perform” rating.

Among 10 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 39 analyst reports since December 16, 2015 according to SRatingsIntel. As per Monday, September 25, the company rating was maintained by Cantor Fitzgerald. The firm has “Buy” rating given on Wednesday, February 7 by Cantor Fitzgerald. H.C. Wainwright maintained the shares of ABEO in report on Thursday, February 8 with “Buy” rating. The firm has “Buy” rating given on Friday, October 6 by Cantor Fitzgerald. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by Jefferies on Thursday, June 1. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Overweight” rating by Cantor Fitzgerald on Thursday, October 12. The firm has “Buy” rating given on Thursday, September 14 by RBC Capital Markets. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) has “Buy” rating given on Monday, April 2 by H.C. Wainwright. Maxim Group maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Tuesday, July 18 with “Buy” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, June 5 report.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *